The program, called BioMe, uses a new platform called “Clinical Implementation of Personalized Medicine through Electronic Health Records and Genomics” or CLIPMERGE to communicate with the EMR and give physicians real-time guidance based on a patient’s genetic profile. Currently, real-time feedback for therapies, based on DNA, is only available for cardiovascular disease, blood clots and high cholesterol.
More Articles on Mount Sinai Medical Center:
Mount Sinai Medical Center Promotes Alex Mendez to Executive VP, CFO
Mount Sinai Medical Center Unveils $440M Hess Center, New Logo
Spreading Ideas About Healthcare’s Future: Q&A With Dr. Kenneth Davis, President and CEO of The Mount Sinai Medical Center
